# SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07322341/  
OnCo record `nct07322341` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of atezolizumab in lung cancer, run by University of Washington, now recruiting.

## Summary

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT07322341 by University of Washington, with a registry enrolment figure of 32 participants, started 2026-10-01 and due to reach its primary completion in 2030-11-01. Interventions recorded: Atezolizumab; CXCR1/2 Inhibitor SX-682; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Biopsy Procedure. Conditions listed: Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Objective response rate. Lung eligibility wording from the registry: "* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK fusion, ROS1 fusion or RET fusions". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07322341
- Phase: 2
- Setting: A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy
- Sponsor: University of Washington
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT07322341: https://clinicaltrials.gov/study/NCT07322341

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07322341.json